Description
OVA Peptide (323-339)
| Catalog number: | B2013054 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 500 ug |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Lyophilized Powder |
| Applications: | molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Ovalbumin, Egg albumin, SERPINB14 |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Sun LZ, Elsayed S, Aasen TB, Van Do T, Aardal NP, Florvaag E, Vaali K. Comparison between ovalbumin and ovalbumin peptide 323-339 responses in allergic mice: humoral and cellular aspects Scand J Immunol. 2010 May;71(5):329-35.
- McFarland BJ, Sant AJ, Lybrand TP, Beeson C. Ovalbumin(323-339) peptide binds to the major histocompatibility complex class II I-A(d) protein using two functionally distinct registers Biochemistry. 1999 Dec 14;38(50):16663-70.
- Xiao M, Xie L, Cao G, Lei S, Wang P, Wei Z, Luo Y, Fang J, Yang X, Huang Q, Xu L, Guo J, Wen S, Wang Z, Wu Q, Tang J, Wang L, Chen X, Chen C, Zhang Y, Yao W, Ye J, He R, Huang J, Ye L. CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy J Immunother Cancer. 2022 May;10(5):e004022.
- Renz H, Bradley K, Larsen GL, McCall C, Gelfand EW. Comparison of the allergenicity of ovalbumin and ovalbumin peptide 323-339. Differential expansion of V beta-expressing T cell populations J Immunol. 1993 Dec 15;151(12):7206-13.
- Moss DL, Mettu RR, Landry SJ. The Serpin-like Loop Insertion of Ovalbumin Increases the Stability and Decreases the OVA 323-339 Epitope Processing Efficiency Biochemistry. 2021 May 25;60(20):1578-1586.
- Fukushima A, Nishino K, Yoshida O, Ueno H. Characterization of the immunopathogenic responses to ovalbumin peptide 323-339 in experimental immune-mediated blepharoconjunctivitis in Lewis rats Curr Eye Res. 1998 Aug;17(8):763-9.
- Zerra PE, Parker ET, Baldwin WH, Healey JF, Patel SR, McCoy JW, Cox C, Stowell SR, Meeks SL. Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity Biomedicines. 2022 Jul 18;10(7):1724.
- Zhu L, Ge F, Yang L, Li W, Wei S, Tao Y, Du G. Alginate Particles with Ovalbumin (OVA) Peptide Can Serve as a Carrier and Adjuvant for Immune Therapy in B16-OVA Cancer Model Med Sci Monit Basic Res. 2017 Apr 28;23:166-172.
- Pfeil J, Simonetti M, Lauer U, Volkmer R, von Thlen B, Durek P, Krhmer R, Leenders F, Hamann A, Hoffmann U. Tolerogenic Immunomodulation by PEGylated Antigenic Peptides Front Immunol. 2020 Oct 9;11:529035.
